Alnylam Pharmaceuticals Inc (ALNY)vsMannKind Corp (MNKD)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
MNKD
MannKind Corp
$3.40
-3.41%
HEALTHCARE · Cap: $1.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 1088% more annual revenue ($4.29B vs $360.78M). ALNY leads profitability with a 12.6% profit margin vs -6.6%. ALNY appears more attractively valued with a PEG of 0.48. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
MNKD
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for MNKD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
15.1% revenue growth
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : MNKD
The strongest argument for MNKD centers on Debt/Equity, Revenue Growth. Revenue growth of 15.1% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : MNKD
The primary concerns for MNKD are Market Cap, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
MNKD carries more volatility with a beta of 1.11 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 29/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
MannKind Corp
HEALTHCARE · BIOTECHNOLOGY · USA
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?